Canertinib

Canertinib (CI-1033) is an investigational pharmaceutical agent under evaluation for its potential in treating various types of cancer. It acts primarily as an irreversible tyrosine-kinase inhibitor, targeting multiple members of the ErbB family of tyrosine kinases.

Canertinib

Mechanism of Action

Canertinib exhibits its inhibitory activity by specifically targeting and irreversibly binding to certain tyrosine kinases. The primary targets of Canertinib include:

• EGFR (Epidermal Growth Factor Receptor): IC50 of 0.8 nM
• HER-2: IC50 of 19 nM
• ErbB-4: IC50 of 7 nM

The IC50 values indicate the concentration of the drug required to inhibit 50% of the enzyme's activity, giving a measure of the drug's potency against each kinase.

Drug Interactions

OATP1B3 Interaction

Canertinib has been identified as a substrate for the transporter OATP1B3 (Organic Anion Transporting Polypeptide 1B3). The interaction with OATP1B3 can influence the hepatic disposition of canertinib, potentially leading to changes in its metabolism and efficacy. This interaction may also pave the way for transporter-mediated drug-drug interactions, thereby affecting the overall pharmacokinetics of canertinib or other co-administered drugs.

It is essential to note that while canertinib is a substrate for OATP1B3, it does not inhibit the activities of both OATP-1B1 and OATP-1B3 transporters. This is crucial in predicting potential drug interactions and the overall safety profile of canertinib.

Clinical Implications

As an experimental drug, canertinib is still undergoing clinical trials to determine its safety, efficacy, optimal dosing, and potential indications in the treatment of cancer. Given its mechanism of action, it may provide a therapeutic option for cancers that are driven by the overactivity of the ErbB family of tyrosine kinases, particularly those that express or overexpress EGFR, HER-2, and ErbB-4.

See Also

• Tyrosine kinase inhibitor
• ErbB family
• Drug-drug interaction
• Pharmacokinetics